This webinar looks at T cell exhaustion. This is recognised as a major challenge in the development of immuno-oncology therapies. Used to describe the loss of effector function due to chronic antigen exposure, it commonly occurs within the tumour microenvironment. This impairs the T cells’ ability to effectively eradicate cancerous cells.
The development of tumour specific immunotherapies focuses on overcoming this exhausted phenotype of T cells to allow targeted killing of the tumour.
This webinar examines:
• The use of advanced flow cytometry to quantify T cell exhaustion phenotypes and cytokine release.
• How Bispecific T cell Engager (BiTE) antibodies in an immune cell killing assay affect T cell exhaustion.
• The influence of target cells on CAR-T cell exhaustion.
About the speaker:
Lauren Kelsey is a scientist in the iQue® applications group, part of the European based BioAnalytics at Sartorius, where she is involved in the research and development of novel applications.
Kelsey’s efforts are focused on the iQue®3 advanced flow cytometry platform where she has supported a number of the immuno-oncology campaigns that are used to exemplify how our technology can be applied to the drug discovery process.Kelsey obtained a degree in Biology at the University of Bath and went on to complete a masters in Regenerative Medicine where she studied mouse pancreatic and liver development before joining Sartorius as an Associate Scientist in 2018.